27-Mar-2024	Half Yearly Report and Accounts

31-Oct-2023	Quarterly Activities/Appendix 4C Cash Flow Report

31-Jul-2023	Quarterly Activities/Appendix 4C Cash Flow Report

28-Apr-2023	Quarterly Activities/Appendix 4C Cash Flow Report

28-Feb-2023	Half Yearly Report and Accounts

15-Feb-2023	Quarterly Activities/Appendix 4C Cash Flow Report

31-Jan-2023	Quarterly Activities/Appendix 4C Cash Flow Report

31-Oct-2022	Quarterly Activities/Appendix 4C Cash Flow Report

29-Jul-2022	Quarterly Activities/Appendix 4C Cash Flow Report

29-Jul-2022	Quarterly Activities/Appendix 4C Cash Flow Report

2-May-2022	Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting

29-Apr-2022	Quarterly Activities/Appendix 4C Cash Flow Report

23-Feb-2022	Kazia Half Year Accounts and Appx 4D

31-Jan-2022	Quarterly Activities/Appendix 4C Cash Flow Report

29-Oct-2021	Quarterly Activities/Appendix 4C Cash Flow Report

30-Jul-2021	Quarterly Activities/Appendix 4C Cash Flow Report

30-Apr-2021	Appendix 4C - quarterly

24-Feb-2021	Kazia half year accounts and Appx 4D

29-Jan-2021	Appendix 4C - quarterly

14-Dec-2020	Kazia receives $1.02m R&D cash rebate

30-Oct-2020	Appendix 4C - quarterly

27-Aug-2020	Kazia Annual Report to shareholders

31-Jul-2020	Appendix 4C - quarterly

20-Feb-2020	Kazia Half Year Accounts and Appx 4D

24-Dec-2019	Kazia receives $1.4m R&D cash rebate

29-Aug-2019	Kazia Annual Report to shareholders

15-Jan-2019	Kazia receives $2.2m R&D cash rebate

8-Oct-2018	Kazia Annual Report to shareholders

29-Aug-2018	Kazia Appendix 4E and financial report

21-Feb-2018	Kazia Half Year Accounts and Appx 4D

16-Oct-2017	Novogen Annual Report to shareholders

30-Aug-2017	Novogen financial report and Appendix 4E

22-Feb-2017	Novogen half year accounts and Appx 4D

19-Oct-2016	Novogen Annual Report to shareholders

17-Mar-2016	Novogen Receives R&D Tax Incentive Cash Refund of $2.8M

22-Feb-2016	Half Yearly Report and Accounts